A Phase 2 interventional study of Tranexamic acid and Tranexamic acid in Post Partum Hemorrhage, sponsored by Inova Health Care Services. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Inova Health Care Services · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 32nd largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 2, and was the 36th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–50 · Women only
Aligarh Muslim University · Sites in India
Ages 18–45 · Women only
London School of Hygiene and Tropical Medicine · Sites in Tanzania
Ages 18+ · Women only
University Hospital, Bordeaux · Sites in France
Ages 18–65 · Women only
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 18 · Phase 4 11
First in 2009; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 120 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 198 across the 50 interventional studies. Of the 35 that completed or were terminated, 7 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 50 has an industry lead sponsor. The 10 most frequent:
Inova Health Care Services is the lead sponsor of 86 studies on the registry; 20 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
Inova Health Care Services has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies testing Tranexamic Acid in Postpartum Hemorrhage that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04304625Phase 3University Hospital, BordeauxTRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA | 2027-06 |
| NCT05562609Phase 3London School of Hygiene and Tropical MedicineTranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk | 2027-09 |
| NCT06754371RenJi HospitalProphylactic Tranexamic Acid Reduces Postpartum Hemorrhage | 2027-01 |
| NCT05370820Inova Health Care ServicesPrevention of Postpartum Hemorrhage With Tranexamic Acid | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section.
The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15 mg/kg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the time of umbilical cord clamping for a non-emergent cesarean section. A maximum of 1 g was administered. TXA serum levels at several time points after delivery were assayed to see if they reach the target plasma concentration of 10 ug/mL. A PK model was constructed for determining the optimal TXA dose administered at parturition.
In part 2 of the study, the investigators aim to compare PKPD endpoints using prophylactic TXA via IV and IM routes administered pre-cord clamp. The investigators will administer 1 g TXA within 10 minutes of skin incision via intravenous infusion (up to n=15), intravenous bolus \< 2 minutes (up to n=15) and intramuscular injection (up to n=15). The investigators will target women undergoing scheduled cesarean delivery > 34 weeks gestation, women undergoing vaginal delivery > 34 weeks of gestation and morbidly obese women (BMI>=40) undergoing either a vaginal or cesarean delivery. The investigators will use advanced modeling techniques to determine time to achieve PKPD targets and duration remaining at those targets. The goal will be to determine how the optimal dose may vary if route of administration is modified. The investigators plan to enroll 45 patients in addition to the 43 that were enrolled during part 1. Our goal is to 30 participants, but the investigators will enroll 45 to account for lost to follow-up. The investigators also aim to enroll 30 patients undergoing vaginal delivery and 30 morbidly obese women (BMI >= 40) undergoing either a vaginal or cesarean delivery but the investigators will enroll 45 patients for each of these groups to account for loss to follow up. In addition, the investigators will enroll 30 pregnant patients receiving no medication acting as the control group, but the investigators will enroll 45 to account for loss to follow up.
The study will enroll 45 additional third trimester pregnant women scheduled for nonemergent cesarean sections. The investigators plan to enroll 30, but to account for lost to follow-up, the investigators will enroll 45. The investigators will also enroll 30 pregnant patients > 34 weeks of gestation undergoing vaginal delivery, and 30 morbidly obese (BMI >= 40) pregnant patients undergoing either vaginal or cesarean delivery. However, the investigators will enroll 45 patients in each of these two groups to account for loss to follow up. The investigators will also enroll 45 patients as a control group that will not receive TXA. The total number of enrolled patients will thus be 223.
A total of 1 g of TXA will be administered to patients prior to fetal delivery via three different routes of administration: IV infusion, IV push, and IM injection. The subjects in each group will be divided into three subgroups:
Group 1: Up to 15 subjects, TXA dose: 1 g, Route: IV infusion over 10 minutes Group 2: Up to 15 subjects, TXA dose: 1 g, Route: IV Push for \<2 minutes Group 3: Up to 15 subjects, TXA dose: 1 g, Route: IM Injection
Plasma sampling: Timing of samples will be relative to the end of drug administration (t = 0) and include: Pre-drug administration, 5-10 minutes, 30-60 minutes, 60-90 minutes, 1.5-3 hours, 3-4 hours, 4-5 hours, 7-8 hours, and 10-18 hours. Each volume of blood draw will be approximately 7-9 mL. Actual times of plasma sampling will be documented. A second IV will be required for participating in the study. Citrated plasma samples will be centrifuged and supernatant will be stored at -80 degree Celsius. Breast milk sampling of no more than 2 mL per time point will occur at time points coinciding with maternal feedings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tranexamic acid · Other: No intervention
Drug: Tranexamic acid · Other: No intervention
Drug: Tranexamic acid · Other: No intervention
Tranexamic Acid 1000 mg administered intravenously via infusion over 10 minutes.
Tranexamic Acid 1000 mg administered intravenously via push over 2 minutes.
Tranexamic Acid 1000 mg administered intramuscularly.
Control group with no administration of Tranexamic Acid.
PK Model Parameter Estimates
Data obtained from assays of TXA in blood, dose group and patient characteristics; parameter estimates in 2 compartment model includes the clearance of the drug (L/hr).
Time frame: Different time points ranging from surgery (T0) to 1 day postpartum.
Pharmacodynamics of Tranexamic Acid
PD model parameters included concentration of TXA causing 50% of maximal fractional inhibition (IC50).
Time frame: Different time points ranging from surgery (T0) to 1 day postpartum.
Estimated Blood Loss
Intraoperative blood loss
Time frame: During surgery
Safety Parameters
Safety parameters such as adverse events (including nausea/vomiting) and serious adverse events
Time frame: During surgery, after surgery while in hospital, 2 weeks and 6 weeks postpartum
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Oct 2027, 57 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Nov 2026 → Oct 2027 and completion Jun 2027 → Apr 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Inova Health Care Services